Please use this identifier to cite or link to this item:
|Title:||Human platelet lysate as a replacement for fetal bovine serum in human corneal stromal keratocyte and fibroblast culture||Authors:||Seidelmann, Nina
Duarte Campos, Daniela F.
Yam, Gary Hin-Fai
Mehta, Jodhbir S.
|Issue Date:||5-Sep-2021||Publisher:||John Wiley and Sons Inc||Citation:||Seidelmann, Nina, Duarte Campos, Daniela F., Rohde, Malena, Johnen, Sandra, Salla, Sabine, Yam, Gary Hin-Fai, Mehta, Jodhbir S., Walter, Peter, Fuest, Matthias (2021-09-05). Human platelet lysate as a replacement for fetal bovine serum in human corneal stromal keratocyte and fibroblast culture. Journal of Cellular and Molecular Medicine 25 (20) : 9647-9659. ScholarBank@NUS Repository. https://doi.org/10.1111/jcmm.16912||Rights:||Attribution 4.0 International||Abstract:||The isolation and propagation of primary human corneal stromal keratocytes (CSK) are crucial for cellular research and corneal tissue engineering. However, this delicate cell type easily transforms into stromal fibroblasts (SF) and scar inducing myofibroblasts (Myo-SF). Current protocols mainly rely on xenogeneic fetal bovine serum (FBS). Human platelet lysate (hPL) could be a viable, potentially autologous, alternative. We found high cell survival with both supplements in CSK and SF. Cell numbers and Ki67+ ratios increased with higher fractions of hPL and FBS in CSK and SF. We detected a loss in CSK marker expression (Col8A2, ALDH3A1 and LUM) with increasing fractions of FBS and hPL in CSK and SF. The expression of the Myo-SF marker SMA increased with higher amounts of FBS but decreased with incremental hPL substitution in both cell types, implying an antifibrotic effect of hPL. Immunohistochemistry confirmed the RT-PCR findings. bFGF and HGF were only found in hPL and could be responsible for suppressing the Myo-SF conversion. Considering all findings, we propose 0.5% hPL as a suitable substitution in CSK culture, as this xeno-free component efficiently preserved CSK characteristics, with non-inferiority in terms of cell viability, cell number and proliferation in comparison to the established 0.5% FBS protocol. © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.||Source Title:||Journal of Cellular and Molecular Medicine||URI:||https://scholarbank.nus.edu.sg/handle/10635/233641||ISSN:||1582-1838||DOI:||10.1111/jcmm.16912||Rights:||Attribution 4.0 International|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|10_1111_jcmm_16912.pdf||1.51 MB||Adobe PDF|
checked on Nov 25, 2022
checked on Nov 17, 2022
This item is licensed under a Creative Commons License